Answers are grounded in this paper and cite their sources.
This study evaluates a minoxidil-loaded nanoemulgel, showing improved follicular delivery and therapeutic efficacy in androgenetic alopecia treatment.
Objective: This research aimed to formulate a minoxidil (MXD) nanoemulgel to optimize follicular delivery, reduce side effects, and improve patient compliance in treating androgenetic alopecia. Methods: A nanoemulgel was developed using the spontaneous emulsification technique, with oleic acid as the base, propylene glycol as the co-surfactant, and Tween 20 as the surfactant. MXD was loaded into the formulation to enhance medication solubilization and skin penetration. Results: The formulated nanoemulgels exhibited a negative zeta potential of (−27 ± 1) and a high entrapment efficiency of (96.2 ± 4.02%). In vitro testing demonstrated sustained release of MXD from the nanoemulsion (NE). Conclusion: The developed MXD nanoemulgel shows promise in enhancing the activity of MXD for the treatment of androgenetic alopecia. The negative zeta potential, high entrapment efficiency, and sustained release profile suggest potential improvements in follicular delivery and therapeutic efficacy. This formulation could offer a more effective and patient-friendly alternative for managing androgenetic alopecia, addressing the limitations associated with conventional MXD formulations.
No takes yet. Share an insight, caveat, or question.
Patidar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: